Oncotarget
AUTHOR INSIGHT, COMMUNITY NEWS & EVENTS BY ONCOTARGET:
- New Study Suggests Panitumumab with Low-Dose Capecitabine as a Safer, Effective Maintenance Treatment for Advanced Colorectal Cancer
A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen.” - SETDB1 Amplification Identified as a Potential Target for New Osteosarcoma Treatment
BUFFALO, NY – February 14, 2025 – A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” - Rare Case of Donor Cell-Derived Blood Cancer Discovered Nine Years After Stem Cell TransplantA new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation.”
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | @Blagosklonny
ABOUT ONCOTARGET.NET:
Visit this page to hear from the distinguished network of authors who continue to publish their research with Oncotarget—an open access biomedical journal dedicated to publishing the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.
For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.
ABOUT ONCOTARGET:
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers.
Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication.
The founding editors of Oncotarget are Dr. Blagosklonny and Dr. Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Dr. Blagosklonny is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity,” Dr. Blagosklonny continues to provide meaningfully important contributions to the scientific community.
CONTACT INFORMATION:
To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.